April 21, 2016
Pharmaceutical company iBio Inc. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1.87 million and attorneys' fees for allegedly fabricating a joint venture to manufacture an Ebola treatment in an effort to pump up the company's value at a time when the disease was ravaging Africa.
October 27, 2014
A shareholder of plant-based pharmaceutical manufacturer iBio Inc. hit the company with a putative class action in Delaware federal court on Friday, alleging that iBio inflated its stock price by misleading investors about its role in manufacturing a new Ebola treatment.